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Molecular imaging of breast cancer has undoubtedly permitted a substantial development of the overall diagnostic accuracy of this
malignancy in the last years. Accurate tumour staging, design of individually suited therapies, response evaluation, early detection
of recurrence and distant lesions have also evolved in parallel with the development of novel molecular imaging approaches. In
this context, positron emission tomography (PET) can be probably seen as the most interesting molecular imaging technology
with straightforward clinical application for such purposes. Dozens of radiotracers for PET imaging of breast cancer have been
tested in laboratory animals. However, in this review we shall focus mainly in the smaller group of PET radiopharmaceuticals that
have lead through into the clinical setting. PET imaging can be used to target general metabolic phenomena related to tumoural
transformation, including glucose metabolism and cell proliferation, but can also be directed to specific hormone receptors that
are characteristic of the breast cancer cell. Many other receptors and transport molecules present in the tumour cells could also
be of interest for imaging. Furthermore, molecules related with the tumour microenvironment, tumour induced angiogenesis or
even hypoxia could also be used as molecular biomarkers for breast cancer imaging.
1. Introduction
PET is a molecular imaging modality in which compounds
labelled with positron emitting radioisotopes are used to
measure biological processes with only trace amounts of
the radiolabelled probes. Molecules labelled with positron-
emitting radionuclides are retained in tissues as a result of
binding to a receptor, or cell entrapment owing to enzyme-
catalyzed conversion after uptake by a cell membrane
transporter. Tomographic images of the distribution of the
radioactivity within the body can be generated and quantita-
tively evaluated by coincidence detection of the gamma rays
resulting from the mutual annihilation of a positron emitted
by the radionuclide and an electron of a nearby atom.
PET radiotracers are molecular probes that can be
designed and synthesized to target very many different
molecular and cellular events. In the specific case of breast
cancer, there is a wide panoply of specific and general targets
one could think about. However, being there a great number
of molecules labelled with different positron emitting
radionuclides (see Table 1) that have been synthesised and
tested in vivo in laboratory animals, only a few of them have
lead through into the clinical setting. In this review, we shall
focus mainly in this smaller group of radiotracers. Papers
focused in PET biomarkers for pre-clinical studies can be
found elsewhere.
2. Glucose Metabolism
Although the number of PET tracers synthesised and tested
in vivo largely exceeds 300, only a fraction has been used
in humans. In addition, probably more than 90% of the
clinical PET studies are performed with the analogue of
glucose 2-[18F]-fluoro-2-deoxy-D-glucose (FDG). Uptake
and metabolism of FDG within tumour cells is higher
than in normal tissue because of increased glycolysis. The
incorporation of FDG to the neoplastic cells is favoured by
the increase of glucose membrane transporters (GLUTs)
which are overexpressed in breast cancer due to the activation
of their genes. FDG is phosphorylated to FDG-6-phosphate
by hexokinase-1, which also has increased activity in tumour
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Table 1: Nuclear characteristics of different selected positron emitters of interest in PET imaging. The maximum positron energy is related
to the maximum theoretical resolution using this radionuclide, in such a way that the smaller the positron emission energy, the better the
resolution than can be achieved. The branching ratio refers to the approximate number of decay events in which a positron is emitted (this
value is 100% for pure positron emitters).
Isotope Half life Maximum positron energy (MeV) Branching ratio (%)
Carbon-11 20min 0.96 ∼100
Fluorine-18 110min 0.63 ∼100
Copper-64 12.7 h 0.58 ∼19
Gallium-68 68min 1.89 ∼88
Bromine-76 16.2 h 3.94 ∼100
Zirconium-89 3.26 days 0.89 ∼23
Iodine-124 4.2 days 2.135 ∼23
(a) (b) (c)
Figure 1: A 60-year-old female (BMI = 37) with a right-sided infiltrating ductal carcinoma was referred for staging. Images were obtained
in a Biograph mCT (Siemens) 60min after i.v. injection of 478MBq of FDG. (a) FDG-PET maximum intensity projection of the thorax. (b)
Axial fused FDG-PET/CT images of the primary tumour in the upper-inner quadrant (arrowhead) (SUV = 5,3), a metastasic lymph node
in the right internal mammary chain (arrow) (SUVmax = 1,38) was found in the PET and histopathologically confirmed. (c) Axial fused
FDG-PET/CT image of a second tumour in the same breast identified in FDG-PET (arrow) (SUVmax = 0,5), not detected by conventional
imaging techniques and biopsy-proven.
cells due both to genetic and allosteric modifications.
Therefore, the detected concentration of labelled FDG is
proportional to the uptake and metabolism of glucose.
In patients with breast cancer, FDG PET/CT results in
improved sensitivity for the detection of both lymph node
infiltration and distant metastases compared to conventional
imaging techniques [1]. Therefore, FDG PET/CT offers
clinically relevant information on the staging of patients
with breast cancer, has prognostic value, and enables
the assessment of therapeutic response and relapse. The
development of PET scanners dedicated to breast (positron
emission mammography) has improved spatial resolution
and sensitivity, allowing its clinical application in the study
of the primary tumour [2].
Tumour uptake of FDG is variable and depends not
only on tumour size, but also on the histological type and
histological grade. The hormone receptor status and other
immunohistochemical factors with prognostic value are also
relevant, such as p53 and Ki-67 expression. FDG uptake is
higher in ductal carcinoma than in lobular carcinoma and
in patients with poor prognostic features as high grade and
hormone receptor negativity [3].
Regarding nodal staging, when FDG PET/CT shows
axillary uptake, the positive predictive value of metastatic
infiltration is greater than 95%. Despite these findings,
lymph node uptake should always be confirmed due to the
low specificity of FDG. In addition, FDG PET/CT can show
disease not detected by conventional imaging techniques in
internal mammary chain and mediastinum [4] (Figure 1).
However, when there is no FDG uptake in the axilla, given
the low sensitivity due to limitations in detecting lymph node
micrometastasis and very small tumours, axillary sentinel
lymph node biopsy should be performed for a correct staging
[5].
FDG PET/CT contributes significantly both in defining
the extent of disease and the choice of appropriate therapy
in patients with advanced tumours (Figure 2). FDG PET/CT
allows early assessment of therapeutic response in patients
receiving neoadjuvant therapy, for evaluation of response to
new biotherapies and for prediction of outcome [6].
FDG PET/CT is superior to CT in the diagnosis of
tumour recurrence in patients with elevated tumour mark-
ers, both in sensitivity, specificity, and overall accuracy, with
changes in clinical management in 50% of patients [7].
3. Proliferation
One of the main hallmarks of tumour cells is their ability to
sustain chronic proliferation, which represents a key target in
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Figure 2: A 47-year-old woman with a left-sided multifocal infiltrating ductal carcinoma, Luminal B, referred for staging. Images were
obtained in a Biograph mCT (Siemens) 60min after i.v. injection of 363MBq of FDG. (a) FDG-PET whole-body maximum intensity
projection: multifocal left-sided breast tumour, lymph node metastasis in the left axilla, left internal mammary chain and mediastinum, left
adrenal gland metastasis, multiple bilateral lung metastases, sternal, spine, and pelvic bone metastases. Physiological uptake was identified
in paraspinal and supraclavicular fossa brown fat, right sternocleidomastoid muscle (arrow), myocardium (∗), kidneys and bladder. (b)
Axial fused FDG-PET/CT image of the multifocal tumour in the left breast (arrows), sternum (arrowhead), and right lung metastasis. (c)
Axial fused FDG-PET/CT image of the left adrenal gland metastasis (arrow). (d) Axial fused FDG-PET/CT image of a vertebral metastasis
(arrowhead).
the scene of the new anticancer therapeutic agents [8]. The
study of the proliferation rate is important not only in the
initial staging and characterization of the tumour, but also in
the assessment of response, both at an early stage (Figure 3)
during the initial treatment schedule—as a way to predict the
clinical outcome—or at the end of the treatment.
Back to 1998, Shields et al. [9] developed and tested 3′-
deoxy-3′-[18F]fluorothymidine (18FLT) as a biomarker for
in vivo imaging of cell proliferation, demonstrating that it
was resistant to degradation in vivo, retained in proliferating
tissues by the action of thymidine kinase 1 and produced
high-contrast images of normal marrow and tumours.
Although 18FLT is not a routine tool in the clinical
practice in breast cancer, it may play an important role
in the staging, monitoring, and prediction of response to
therapy agents [10]. Moreover, 18FLT strongly correlates with
the immunohistochemical proliferation index ki-67 [11].
18FLT-PET can be of value as an early response predictor
for different chemotherapeutic agents. In a prospective
study in 20 patients with stages II–IV breast cancer under
docetaxel treatment, Contractor et al. [12] aimed to establish
biomarkers indicating clinical response to taxanes. Patients
underwent a baseline dynamic 18FLT-PET scan followed by
a scan 2 weeks after initiating the first or second cycle
of docetaxel. 18FLT-derived PET variables were compared
with anatomic response after 3 cycles and concluded that
changes in tumour proliferation assessed by 18FLT early
after initiating docetaxel chemotherapy could predict lesion
response with good sensitivity. Furthermore, Kenny et al.
[13] demonstrated that 18FLT can detect changes in breast
cancer proliferation as early as at 1 week after 5-fluorouracil,
epirubicin, and cyclophosphamide therapy. Decreases in
the irreversible trapping constant and the standardized
uptake value (SUV) at 1 week discriminated between clinical
response and stable disease. In an effort to find simplified
valuable 18FLT-PET uptake measures, Lubberink et al. [14]
studied with a dynamic 18FLT-PET scan 15 patients with
locally advanced breast cancer both prior to and after the
first cycle of chemotherapy with fluorouracil, epirubicin or
doxorubicin, and cyclophosphamide. The authors concluded
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Figure 3: (a) Baseline PET/CT images obtained in a BiographDuo LSO (Siemens) 75min after injection of 405MBq of 18FLT in a 47-year-old
woman with a right-sided infiltrating ductal carcinoma (SUVmax = 5,42) (arrow) and lymph node uptake (SUVmax = 1,85) (arrowhead).
Physiological bone marrow uptake was identified. (b) PET/CT images obtained 75min after injection of 529MBq of 18FLT after one cycle of
neoadjuvant therapy. SUVmax decreased to 3,57 in the primary tumour and to 0,80 in the lymph node, consistent with metabolic response.
(a) (b)
∗
(c)
Figure 4: Axial PET (a), CT (b), and fused PET/CT (c) images obtained in a Biograph Duo LSO (Siemens) two hours after i.v. injection
of 368MBq of FMISO, in a 64-year-old woman with a left-sided triple negative infiltrating ductal carcinoma, T2N1M0. Peripheral tumour
uptake of FMISO (SUVmax = 1,44) consistent with hypoxia (arrow), and inside tumour lack of activity due to central necrosis (∗) were
observed. Physiological uptake in muscles and mediastinum was identified.
that tumour-to-whole blood ratio may be preferred to SUV
as a simplified measure for monitoring response.
4. Hypoxia
Another important hallmark of cancer disease is hypoxia.
This microenvironmental factor facilitates the metastasic
spread and is related to poor response to radiation,
chemotherapy, genetic instability, and selection for resis-
tance to apoptosis due to its effect on various metabolic,
molecular-genetic, and pathophysiologic adaptive processes.
Tumour hypoxia is a condition of insufficient O2 to
support metabolism and occurs when tumour outgrows its
vascularity supply. It has been identified as one of major
independent prognostic factors influencing response to
therapy and overall survival in many malignancies, including
breast cancer [15, 16].
The occurrence of hypoxia in human tumours has in
most cases been inferred from histologic findings and from
evidence of hypoxia in animal tumour studies. In vivo
demonstration of hypoxia required tissue measurements
with oxygen electrodes and the invasiveness of this technique
has limited its applications. Consequently, there has been a
growing impetus to develop noninvasive imaging methods
to detect and assess tumour hypoxia.
The first clinical studies to image hypoxia using PET
were based on halogenated tracers of 2-nitroimidazoles, such
as [18F]fluoromisonidazole (18FMISO) [17]. This compound
diffuses through cell membranes and when tissular pO2 is
below 10mm Hg becomes reduced in viable cells by nitrore-
ductase and once reduced is accumulated intracellularly. Two
to four hours after injection, the retention is considered to be
specific to cellular hypoxia (Figure 4).
Antiangiogenic therapy has been thought to hold signif-
icant potential for the treatment of cancer. However, in the
specific case of breast cancer, new research using preclinical
models suggests that antiangiogenic agents actually increase
invasive and metastatic properties of breast cancer cells by
augmenting the population of cancer stem cells by generating
intratumoural hypoxia [18]. Albeit no results from human
studies have been reported, PET imaging of hypoxia could
help shed some light on this cutting-edge story.
Although there are not many published papers on
18FMISO in breast cancer, its utility has been well established
in other tumours, such as glioblastoma multiforme, rectal,
lung and head and neck carcinomas [19].
Rajendran et al. [20] compared the glucose metabolism
(FDG-PET) and hypoxia (18FMISO-PET) in four different
types of tumours, including seven patients with breast
cancer. They concluded that although hypoxia is a general
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factor affecting glucose metabolism, some tumours can have
modest glucose metabolism, whereas some highly metabolic
tumours are not hypoxic, showing discordance in tracer
uptake that can be tumour-type-specific.
5. Radiolabelled Choline Derivatives
Transformation from choline to phosphocholine increases
with malignant transformation and progression of mam-
mary epithelial cells in vitro. Furthermore, increase in phos-
phocholine can be attributed to expression of the enzyme
choline kinase-α. It is also important to consider that both
choline kinase activity and cellular phosphocholine levels
are regulated by the growth factor receptor-MAPK pathway,
the same one that modulates estrogen-independent growth
[21].
Once the fundamentals for the use of N-[11C]methyl-
choline (11C-choline) were established, Contractor et al. [22]
showed that breast tumours were well visualized in 30 of
32 patients with good tumour background ratios, albeit
surprisingly a poor association was found with tumour size,
estrogen receptor, progesterone receptor, human epidermal
growth factor receptor-2, Ki-67, and nodal status.
Albeit the exact biological mechanism of increased 11C-
choline uptake in certain tumours is unknown, choline is
required for membrane synthesis in actively proliferating
cells. Consequently, it could be hypothesized that 11C-
choline uptake should be higher in cells undergoing prolifer-
ation. More recently, the same group [23] has demonstrated
in a set of 21 patients with estrogen receptor positive breast
cancer that choline metabolism assessed by 11C-choline PET
and proliferation determined by 18FLT-PET were correlated
in ER-positive breast cancer, concluding that high 11C-
choline uptake is a measure of cellular proliferation in this
setting.
Regarding the use of fluorine labelled choline derivatives
in diagnosis of breast cancer, no reports can be found
in the literature, apart from an incidental finding in a
male patient with elevated PSA levels that was studied by
18F-fluorocholine PET for possible diagnosis of prostate
cancer [24]. PET/CT images revealed focal uptake in the left
breast that was found by biopsy to be an invasive ductal
breast carcinoma. Prostate biopsy also revealed prostate
cancer corresponding to an area of increased prostatic 18F-
fluorocholine uptake.
6. Estrogen Receptors
Endocrine therapy targeting steroid receptors remains the
most effective form of systemic therapy in breast cancer.
Thus, receptor ligands such as fluorine-labelled estradiol
offer the possibility to study the presence of estrogen
receptors (ER) in both primary and tumour metastasis, and
may be a useful tool in the therapeutic management and
prognostic evaluation of breast cancer.
Already back to 1988, Mintun et al. [25] pioneered in
vivo molecular imaging of breast cancer with PET using
the estrogen receptor ligand 16α-[18F]-fluoro-17β-estradiol
(18F-FES) in a set of 13 patients with primary breast tumours.
They found an excellent correlation between uptake of 18F-
FES and estrogen-receptor concentration measured in vitro
after excision of the lesions.
Nowadays, whole-body PET with 18F-FES can be seen
as a unique method to noninvasively obtain molecular
information of ER expression. No other procedure can
provide information on a whole body basis of the ER status in
metastasic breast cancer. It is well known that ER expression
at metastasic sites might not be the same as the ER expression
at the primary disease due to relatively common phenotypic
changes. In any case, loss of ER expression is more common
than gain of ER expression.
Many different studies have shown that 18F-FES PET
can reliably detect ER-positive tumour lesions and that 18F-
FES uptake correlates with ER expression as measured by
immunohistochemical methods. Furthermore, low 18F-FES
uptake has been reported to be a strong predictor for failure
of antihormonal therapy. For a comprehensive review of 18F-
FES PET, see [26] and references therein.
Imaging ER expression by PET can be used to identify,
characterize, and follow treatment response to multiple
lesions in the same patient. 18F-FES PET also has great
potential for evaluating ER activity in metastasic breast
cancer, in which patients have many bone lesions that
are difficult to biopsy and prone to false-negative ER by
immunohistochemistry [27].
Kurland et al. [28] have recently analysed between-
patient and within-patient variability in ER binding by 18F-
FES-PET and have shown that both 18F-FES uptake and the
18F-FES/FDG ratio varied greatly between patients but were
usually consistent across lesions in the same scan. These
results seem to provide a reasonable summary of some kind
of “synchronous ER expression” for most patients. However,
imaging the entire disease burden remains important to
identify the subset of patients with mixed uptake, who
may be at a critical point in their disease evolution. These
results are also supported by van Kruchten et al. [29] that
have shown whole-body imaging of ER expression with
18F-FES-PET as a very valuable additional diagnostic tool
when standard workup is inconclusive. With the exception
of liver metastases, 18F-FES PET can be used to support
therapy decisions by improving diagnostic understanding
and providing information on ER status of tumour lesions.
In a very thorough study with 312 18F-FES-PET scans
in 239 patients with documented ER positive primary
breast cancer, Peterson et al. [30] demonstrated that 18F-
FES imaging protocols may be simplified without sacrificing
the validity of the results, as calculation of 18F-FES SUV
should be sufficient to assess tracer uptake for the purpose
of inferring ER expression.
7. Progesterone Receptors
Hormone-sensitive breast cancer is less aggressive than
hormone-resistant disease; hormone-sensitive disease occurs
more commonly in postmenopausal women and is charac-
terized by longer disease-free and overall survival.
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The presence of the progesterone receptor (PR) increases
the likelihood of hormone responsiveness, while proges-
terone receptor-negative tumours are less responsive to
therapy, perhaps suggesting that PR may be necessary
for adequate therapeutic outcome. Furthermore, the cross-
relationship between estrogen and progesterone receptors—
being the former a key transcription factor for the activation
of the latter—could suggest that the estrogen response path-
way may not be functional in these tumours. In this scenario,
noninvasive detection and quantification of PR positive or
PR negative lesions would be of enormous value, especially
considering that discordance of hormone receptor status
between the primary tumour and metastatic disease is not
uncommon. This difference may influence patient prognosis
and response to therapy. Dehdashti et al. [31] have recently
used in humans for the first time a fluorine-18-labelled
PR-specific ligand and shown that it can be used to assess
the PR status of individual breast cancer lesions. However,
no significant correlation was demonstrated between the
SUVmax and distribution volume ratio for the tracer uptake
and receptor status, likely because of small sample size.
8. Radiolabelled Derivatives of P-Glycoprotein
Substrates and Inhibitors
Resistance to multiple chemically different drugs is a well-
known phenomenon in oncology. Even though the exact
cause remains elusive and is multifactorial, membrane
proteins that actively remove drugs from the cell are known
to play a relevant role.
The best characterized of such drug-resistance proteins
is P-glycoprotein (Pgp) (also known as multidrug-resistance
protein 1 and ABCB1), amember of the ATP-binding cassette
transporters family, which transports substrates across the
cell membrane in different conditions. Another relevant
member of this family is the breast cancer resistance protein
(BCRP, also known as ABCG2). Several PET radiotracers
for visualization of Pgp have been described so far [32–36]
including carbon-11- and fluorine-18-labelled derivatives of
Pgp substrates such as verapamil or loperamide and Pgp
inhibitors such as elacridar and tariquidar. The former per-
mit in vivo visualization of Pgp function, while the latter can
be understood as surrogate markers of Pgp expression levels.
In any case, few Pgp-directed PET tracers have been used
in the clinical setting in humans, being probably the paper
by Kurdziel et al. [37] describing the human dosimetry and
tumour distribution of 18F-fluoropaclitaxel in breast cancer
patients one of the more recent reports. These authors show
that, albeit in a very small series with only three patients,
tumour accumulation of the radiotracer could be detected in
all cases and that 18F-fluoropaclitaxel distribution could be
used as a surrogate biomarker for paclitaxel and potentially
other chemotherapeutic agents.
9. Integrin Ligands
Integrins are obligate heterodimeric proteins involved in cell-
cell interaction, interaction of cells with the extracellular
matrix, signal transmission, and apoptosis. They are key
components of the cell machinery involved in cell signalling,
shape, and motility and are part of the complex transduction
mechanisms that permit cells to be aware of the changes
in their surrounding environment and also participate in
the communication of the intracellular changes to the
outside.
The αvβ3/5 subclasses of the integrin family are of
particular interest as they are upregulated in tumour neo-
vasculature and on several types of tumour cells (including
breast cancer), making them a potentially valuable diagnostic
tool. Furthermore, an association between expression of
αvβ3/5 and relapse-free survival in breast cancer has been
reported [38], suggesting a prognostic value of imaging such
receptors.
Integrin αvβ3 has been demonstrated to be involved in
tumour transformation, angiogenesis, local invasiveness, and
metastatic potential. A number of different positron emitter-
labelled ligands have been developed to image integrins,
and some have already been used in breast cancer patients.
Among them, arginine-glycine-aspartic acid (RGD) peptide
ligands have high affinity for these integrins and can be
radiolabeled for PET imaging of angiogenesis or tumour
development [39].
The ability to noninvasively visualize and quantify αvβ3
integrin expression via RGD will provide new opportunities
to document tumour integrin levels, more appropriately
select patients who are candidates for antiangiogenic treat-
ment and monitor treatment effectiveness in patients with
integrin-positive findings.
Back to 2008, Beer et al. [40] reported the use of
18F-Galacto-RGD in a group of 16 breast cancer patients
and demonstrated tracer uptake in all primary tumour
lesions and metastases (Figure 5) although 18F-Galacto-
RGD uptake in the lesions was very heterogeneous in all
cases, suggesting elevated but widely varying levels of αvβ3
expression in human breast cancer. Immunohistochemical
analysis revealed that the detected signal represented a
mixture of tracer binding on neovasculature and on tumour
cells.
More recently, Kenny et al. [41] have used the cyclic
peptide-polymer conjugate 18F-fluciclatide (18F-AH111585),
an aminooxy-functionalized double-bridged RGD derivative
with optimized stability. 18F-fluciclatide could be used to
detect primary and metastatic breast cancer lesions and
could be of value for imaging tumours and for pharma-
codynamic monitoring of antiangiogenic therapies. In any
case, tumour uptake largely varied among individuals and
different tumour types, and even between tumours of the
same type within one patient. Tomasi et al. [42] have focused
on the best quantification approach to analyse the kinetics of
18F-fluciclatide in breast cancer patients.
Other RGD-derived radioligands based on the dimeric
RGD moiety such as [18F]FPPRGD2 have also been recently
tested in humans [43]. In addition, a quite large number
of different derivatives targeted to image the expression of
αvβ3 integrin have been developed in the last years and tested
in vivo in small animals, including some very promising
gallium-68 labelled RGD peptides [44].
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Figure 5: Maximum-intensity projection of 18F-galacto-RGD PET
in a 70-year-old patient with invasive ductal breast cancer of left
breast (arrow, open tip), axillary lymph-node metastases on left
side (arrow, open tip, dotted line), an osseous metastasis to the
sternum (arrow, closed tip). Reprinted by permission of the Society
of Nuclear Medicine from Beer et al. [40], Figure 2.
10. Monoclonal Antibodies
Immuno-PET has largely been seen as an exciting option
for better understanding the in vivo behaviour and efficacy
of monoclonal antibodies (mAbs) in individual patients.
Very many papers have been written to describe the benefits
of these visible magic-bullet approach—see [45, 46] and
references therein—, and many radiolabelled antibodies and
derivatives have been used for small animal imaging.
For labelling intact antibodies with a low-clearance
kinetics, longer-lived radioisotopes such as zirconium-89 or
iodine-124 are the election of choice, while for radiolabelling
mAbs fragments or constructs (minibodies, affibodies, dia-
bodies, etc.) which are more rapidly cleared from the body,
shorter-lived positron emitters such as gallium-68 or copper-
64 might be ideally suited.
Currently, 12mAbs have been approved by the FDA
for the treatment of cancer, all being intact mAbs [47].
Seven of the mAbs have been approved for the treatment of
hematological malignancies, and five for the therapy of solid
tumours [48]. However, it has only been very recently that
several crucial concurrent achievements have been obtained
to allow broad-scale application of (mainly) 89Zr-immuno-
PET in clinical mAb development and applications. The
aforementioned advances are related with the production
and commercial availability of 89Zr for clinical use and the
development of chelates for facile and stable coupling of 89Zr
to mAbs.
Overexpression of HER2/neu in breast cancer is corre-
lated with a poor prognosis. It may vary between primary
tumours and metastatic lesions and change during the treat-
ment. Therefore, there is a need for a new means to assess
HER2/neu expression in vivo. A 68Ga-labeled HER2 deriva-
tive affibody has been used to monitor HER2/neu expression
in breast cancer xenografts [49] and preliminary results
suggest that it could be sensitive enough to detect different
levels of HER2/neu expression in vivo. ThemAb trastuzumab
targets the human epidermal growth factor receptor kinase
(ERBB orHER) signaling network and has a history as a ther-
apeutic for metastatic or adjuvant treatment of oncological
disease. Upregulation of the ERB2 (HER2/neu) receptor has
been associated with metastasis and poor prognosis in many
cancers, including breast cancer. Specifically, HER receptors
stimulate growth and regulate survival and differentiation.
Because of variable HER2/neu receptor expression over time,
noninvasive and dynamic measurement methods would
be ideal for monitoring potential treatment and disease
prognosis.
However, there is only one paper published so far
describing the use of immuno-PET in humans and just in
fourteen patients [50] and an additional case report [51],
but it concludes that PET scanning after administration
of 89Zr-trastuzumab allows visualization and quantifica-
tion of uptake in HER2-positive lesions in patients with
metastatic breast cancer. The PET images obtained with
89Zr-trastuzumab revealed high spatial resolution and a
good signal-to-noise ratio. Excellent tumour uptake and
visualization of HER2-positive metastatic liver, lung, bone,
and brain tumour lesions were obtained. 89Zr-trastuzumab
PET visualized bony metastatic disease. These early studies
show great promise for the potential of 89Zr-trastuzumab in
immuno-PET.
11. Exotic Sugar-Like Tracers
A number of different tracers targeting diverse cellular
biochemical mechanisms involved in breast cancer have
been developed, synthesised, and tested in breast cancer
xenograft models. Although an exhaustive list is well beyond
the scope of this paper, it is worth citing a couple of very
recent articles describing the use of sugar-like derivatives
as alternatives to FDG for tumour imaging: a fluorine-
18-labelled inositol derivative [52] and a fluorine-18-
labelled fructose derivative used to image GLUT5 transporter
[53].
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